Gain Therapeutics, Inc. (GANX) stock
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.11−0.07 (-5.93%)
Close on Nov 18, 2026Market cap $48.44MP/E –Yield –
Gain Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Gain Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$19.29M. For fiscal 2025 it was -$18.71M. The highest annual figure on record is -$3.48M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$18.71M | – |
| FY2024 | Dec 31, 2024 | -$20.35M | – |
| FY2023 | Dec 31, 2023 | -$22.25M | – |
| FY2022 | Dec 31, 2022 | -$17.78M | – |
| FY2021 | Dec 31, 2021 | -$13.83M | – |
| FY2020 | Dec 31, 2020 | -$3.48M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.68M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.09M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.33M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.46M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.38M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.41M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.89M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.73M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.23M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.75M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.18M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.29M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.64M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.51M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.47M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.62M | – |
| Q3 FY2020 | Sep 30, 2020 | -$819.09K | – |
| Q2 FY2020 | Jun 30, 2020 | -$532.47K | – |
| Q1 FY2020 | Mar 31, 2020 | -$512.26K | – |
See a number that looks wrong?